Pulmonary drug delivery is a route of administration in which patients use an inhaler to inhale its medications, and drugs are absorbed into the bloodstream via the lung mucous membrane. It provides direct access to disease in the treatment of respiratory diseases, while providing an enormous surface area and a relatively low enzymatic, controlled environment for systemic absorption of medications.

Pulmonary drug delivery offers several advantages as a route of administration for the treatment of systemic diseases compared with intravenous, oral, buccal, transdermal, vaginal, nasal or ocular administration.

Market Dynamics

The key market players are focused on organic growth strategies such as product approval by regulatory authorities to expand its product portfolio is expected to drive the global pulmonary drug delivery systems market growth over the forecast period. For instance, in July 2020, Novartis AG, a pharmaceutical company, announced that the European Commission (EC) has approved Enerzair Breezhaler, as a maintenance treatment of asthma in adult patients. The approval also includes an optional digital companion with sensor and app that provides inhalation confirmation, medication reminders and access to objective data to better support therapeutic decisions.

The increasing research and development activities by key market players for the treatment of pulmonary diseases is expected to drive the market growth over the forecast period. For instance, in December 2020, Intas Pharmaceuticals Ltd., announced that the company was focused on developing advanced inhalation formulation having fundamental advantages in the therapy of diseases of the respiratory tract, including asthma and Chronic Obstructive Pulmonary Disease with Orally Disintegrating Tablet Technology. The Drug delivery system designed for rapid disintegration of the product ensuring faster onset of action. This technology is used for several molecules to facilitate ease of administration and improved patient compliance & convenient dosing for paediatric, geriatric, and psychiatric patients with respiratory diseases.

Key features of the study:

• This report provides an in-depth analysis of the global pulmonary drug delivery systems marketand provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global pulmonary drug delivery systems marketbased on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include 3M Health Care, Allied Healthcare Products, Inc., AstraZeneca, Boehringer Ingelheim International GmbH., CareFusion Corporation, GF Health Products, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals, PARI Respiratory Equipment, Inc., and Koninklijke Philips N.V.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global pulmonary drug delivery systems market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pulmonary drug delivery systems market

Detailed Segmentation:

• Global Pulmonary Drug Delivery Systems Market, By Product Type:
  • Nebulizers
  • Dry Powder Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
• Global Pulmonary Drug Delivery Systems Market, By Application:
  • Asthma
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Cystic Fibrosis
  • Allergic Rhinitis
  • Others
• Global Pulmonary Drug Delivery Systems Market, By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Pulmonary Drug Delivery Systems Market, By Region:
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • 3M Health Care
  • Allied Healthcare Products, Inc.
  • straZeneca
  • Boehringer Ingelheim International GmbH.
  • CareFusion Corporation
  • GF Health Products, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Omron Healthcare, Inc.
  • Glenmark Pharmaceuticals
  • PARI Respiratory Equipment, Inc.
  • Koninklijke Philips N.V.